Choi Samantha and Tawil Bill*

Department of Bioengineering, University of California, Los Angeles (UCLA), USA

*Corresponding Author: Tawil Bill, Department of Bioengineering, University of California, Los Angeles (UCLA), USA.

Received: September 08, 2026; Published: October 21, 2026

Osteoporosis is a chronic metabolic bone disease that is projected to grow in both diagnosis and market size as the global age rises. It is defined as any significant loss in bone mass that can lead to higher fracture risk and morbidity among patients. Current diagnostic standards use fracture risk assessments tools and x-ray absorptiometry to determine a patient’s risk profile. Healthy lifestyle choices such as regular exercise and dieting can limit a person’s risk of osteoporosis. 90% of all bone growth occurs during infancy and puberty, creating a driving importance in developing healthy habits early. Primary and secondary osteoporosis are defined by their causes with primary osteoporosis being a result of aging or menopause while secondary osteoporosis is a wider categorization that holds all other osteoporosis causes. Because osteoporosis risk rises with age, the global market CAGR is expected to rise between 2025 to 2034 globally. North American, Asian-Pacific, and European markets are all expected to rise following this trend due to both the global population age averages increasing as well as favorable regulatory policies and awareness campaigns. Drugs are the current dominant product on the market, but research looks to new tissue engineering solutions both as drug delivery scaffolds and repair grafts.

Keywords: Osteoporosis; Disease Market; Tissue Engineering; Market Analysis

References

1. Sözen T., et al. “An overview and management of osteoporosis”. European Journal of Rheumatology1 (2017): 46-56.
2. Lin Julie T MD and Lane Joseph M MD. “Osteoporosis: A Review”. Clinical Orthopaedics and Related Research 425 (2004): 126-134.
3. Rachner T., et al. “Osteoporosis: now and the future”. The Lancet 377 (2011): 1276-1287.
4. Sterling Julie A and Scott A Guelcher. “Biomaterial Scaffolds for Treating Osteoporotic Bone”. Current Osteoporosis Reports 1 (2014): 48-54.
5. Osteoporosis Treatment Market Size to Hit USD 20.83 Billion by 2034.
6. Osteoporosis Market Trends and Growth Analysis.
7. Osteoporosis Treatment Market Size, Growth, Share | Forecast, 2032.
8. E Michael Lewiecki., et al. “Healthcare Policy Changes in Osteoporosis Can Improve Outcomes and Reduce Costs in the United States”. JBMR Plus9 (2019): e10192.
9. Mithal A., et al. “The Asia-Pacific Regional Audit-Epidemiology, Costs, and Burden of Osteoporosis in India 2013: A report of International Osteoporosis Foundation”. Indian Journal of Endocrinology and Metabolism 4 (2014): 449-454.
10. Chandran M., et al. “Prevalence of osteoporosis and incidence of related fractures in developed economies in the Asia Pacific region: a systematic review”. Osteoporosis International6 (2023): 1037-1053.
11. “Osteoporosis Drugs Market Size, Trends, Share & Growth Drivers 2026 - 2031”. Mordor Intelligence 28 Jan. (2026).
12. Year: 2024 |, Base. Postmenopausal Osteoporosis Treatment Market Report, Market Size & Revenue, Share, Forecast 2024-2030.
13. FDA-Approved Medications for Osteoporosis Treatment.
14. Tabatabaei-Malazy Ozra., et al. “New Horizons in Treatment of Osteoporosis”. DARU Journal of Pharmaceutical Sciences1 (2017): 2.
15. Hayes J and Sambrook P. “Drug Evaluation Oncologic, Endocrine & Metabolic: Alendronate (Fosamax®): clinical utility in metabolic bone disease”. Expert Opinion on Investigational Drugs12 (1996): 1691-1705.
16. McClung M and Geusens P. “Review of risedronate in the treatment of osteoporosis”. Expert Opinion on Pharmacotherapy12 (2001): 2011-2025.
17. Andrea V Haas and Meryl S LeBoff. “Osteoanabolic Agents for Osteoporosis”. Journal of the Endocrine Society8 (2018): 922-932.
18. Chen J and Sambrook P. “Antiresorptive therapies for osteoporosis: a clinical overview”. Nature Reviews Endocrinology 8 (2012): 81-91.
19. Cameron YS Lee. “Medication-Relate Osteonecrosis of the Jaws (MRONJ): A Global Health Concern in Medicine and Dentistry”. SF Journal of Public Health 2 (2018): 4.
20. “Mountainside Medical”. Mountainside Medical.
21. Rosen HN., et al. “Denosumab for osteoporosis”.
22. “FDA Clears Abaloparatide for High-Risk Osteoporosis Patients”. Medscape.
23. University Hospital, Basel, Switzerland. “Effectiveness of Adipose Tissue Derived Mesenchymal Stem Cells as Osteogenic Component in Composite Grafts Versus Acellular Bone Graft Substitutes for Augmentation in the Treatment of Proximal Humeral Fractures as Model for Fractures of Osteoporotic Bone - a Prospective Randomized First in Men Proof of Principle Trial”. Clinical trial registration no. NCT01532076, clinicaltrials.gov, 16 Sept. (2014).
24. Sun T., et al. “Bone Tissue Engineering Scaffolds for Bone Aging: Drug Delivery and Microenvironment Regulation”. Tissue Engineering - Part B: Reviews 18 (2026): 19373341251379774.
25. “Osteoporosis Drugs Market”. Market.
26. Tu KN., et al. “Osteoporosis: A Review of Treatment Options”. P&T2 (2018): 92-104.
27. Yang Haisheng. “Osteogenesis and Bone Regeneration”. IntechOpen (2019).
28. Caplan AI. “Bone Development”. In Ciba Foundation Symposium 136 - Cell and Molecular Biology of Vertebrate Hard Tissues (eds D. Evered and S. Harnett) (2007).
29. Berendsen Agnes D and Bjorn R Olsen. “Bone Development”. Bone 80 (2015): 14-18.
30. “General Facts”. Bone Health & Osteoporosis Foundation.
31. Sochett Etienne. “Healthy Bones - Activity and Nutrition”. Paediatrics and Child Health5 (2002): 315-317.
32. C Christodoulou and C Cooper. “What is osteoporosis?”. Postgraduate Medical Journal929 (2003): 133-138.
33. Amarnath S S., et al. “Classification of Osteoporosis”. Indian Journal of Orthopaedics1 (2023): 49-54.
34. Peter R Ebeling., et al. “Secondary Osteoporosis”. Endocrine Reviews2 (2022): 240-313.
35. Stein Emily and Elizabeth Shane. “Secondary Osteoporosis”. Endocrinology and Metabolism Clinics of North America 1 (2003): 115-134.
36. Ball JR., et al. “Delivery of Growth Factors to Enhance Bone Repair”. Bioengineering (Basel)11 (2023): 1252.
37. McGreevy C and Williams D. “Safety of drugs used in the treatment of osteoporosis”. Therapeutic Advances in Drug Safety 4 (2011): 159-172.
38. Huang X., et al. “Physical Stimulations for Bone and Cartilage Regeneration”. Regenerative Engineering and Translational Medicine 4 (2018): 216-237.
39. Leucht Philipp., et al. “Effect of Mechanical Stimuli on Skeletal Regeneration around Implants”. Bone4 (2007): 919-930.
40. Augat Peter., et al. “The Role of Mechanical Stimulation in the Enhancement of Bone Healing”. Injury 52 (2021): S78-83.
41. Osteoporosis Treatment Market Size to Hit USD 21.79 Billion by 2035.
42. Pharmacy | Vezeeta.com.
43. Prolia Injection 60mg/Ml: Uses, Dosage, Side Effects, Generic, Price - Osudpotro.

Citation

Citation: Choi Samantha and Tawil Bill. “Osteoporosis: Overview of Disease and the Current Market". Acta Scientific Medical Sciences 10.11 (2026): 46-53.

Copyright

Copyright: © 2026 Choi Samantha and Tawil Bill. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.